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What does this paper add to the literature? 
This is the first study to show that performing prehabilitation in patients with rectal cancer 
undergoing neo-adjuvant chemoradiotherapy is feasible, safe and well tolerated by patients. 
With no reported interruption to each participant’s planned clinical management, these findings 
support progression to a large powered multi-centred trial.  
Abstract  
Background. Rectal cancer patients undergoing NACRT (neo-adjuvant chemoradiotherapy) 
experience physical deterioration and reductions in their quality of life. This feasibility study 
assessed pre-habilitation (a walking intervention) before, during and after NACRT to inform a 
definitive multi-centred RCT. 
 
Methods. Patients planned for NACRT then potentially curative surgery were approached 
(August 2014 - March 2016) (www.isrctn.com; 62859294). Baseline physical and psycho-social 
measures using validated tools were performed before NACRT. Participants were randomised 
to either the intervention (exercise counselling session followed by 13-17 weeks telephone-
guided walking programme) or control group (standard care). Follow-up testing was undertaken 
1-2 weeks before surgery. 
 
Results. Of 296 screened patients, 78 were eligible (26%) and 48 were recruited (62%): 65% male; 
mean age 65.9 years (range 33.7-82.6). Mean intervention duration was 14 weeks with 75% 
adherence. 83% of participants completed follow-up testing and both groups recorded 
reductions in daily walking, however, the reduction was less in the Intervention group. 
Participants reported high satisfaction and fidelity to trial procedures. 
  
Conclusion. This study demonstrates that prehabilitation is feasible in rectal cancer patients 
undergoing NACRT. Good recruitment, adherence, retention and patient satisfaction rates 
support the development of a fully powered trial.  The effects of the intervention on physical 
outcomes were promising.   
 
Introduction 
Rectal cancer is the third commonest cause of cancer death in the UK with long-term survival 
improving as a result of earlier diagnosis and advances in surgery and chemo-radiotherapy 1. For 
patients with margin threatening or low rectal cancers, long-course neo-adjuvant 
chemoradiotherapy (NACRT) can be first-line treatment to down-stage the tumour, to either 
optimise the chances of achieving negative surgical resection margins or to result in complete 
response removing the immediate need for major pelvic surgery 2,3,4,5. The 5-6 weeks of NACRT 
can be challenging for patients with severe acute side effects estimated to occur in nearly 22%, 
including haematological toxicity, sepsis, enteritis, radiological dermatitis and cardiotoxicity 6. 
These can lead to deteriorations in physical and social functioning, accompanied by increased 
levels of incontinence, embarrassment and fatigue that can persist for many months or years 7,8,9. 
With many patients having low levels of physical fitness prior to starting neo-adjuvant treatment, 
NACRT has the potential to make a patient physically vulnerable prior to undergoing surgery 10.  
  
It is widely accepted that any patient approaching major surgery with poorer physical fitness 
(aerobic capacity, muscular strength, endurance, flexibility and body composition) is at greater 
risk of post-operative complications, including mortality 11,12,13,14,15. As a result, prehabilitation (an 
intervention to enhance the functional capacity of the individual to enable him or her to 
withstand a stressful event) has become an evolving area of interest with studies assessing 
feasibility of such an intervention and influence on post-operative outcomes 16,17,18. Such studies 
vary in their methodology and patient population; however, a recent systematic review of 9 
studies (435 patients) that had performed prehabilitation in patients undergoing major 
abdominal surgery concluded that prehabilitation decreased the incidence of post-operative 
major complications (OR: 0.59, 95%CI: 0.38-0.91), especially pulmonary 19.  
 
Specifically relating to rectal cancer patients, current standard care creates a minimum 
timeframe of 2 months from completion of NACRT to potential surgery providing a window of 
opportunity for prehabilitation prior to undergoing major surgery. This is an opportunity that 
patients going from diagnosis straight to surgery within current target treatment timelines do 
not have (Scottish Government target: 31 days) 20.  
 
In one non-randomised study, researchers reported a reduction in physical fitness [using 
cardiopulmonary exercise testing (CPET)] in39 patients that had completed long-course NACRT. 
The intervention group then underwent three supervised aerobic sessions per week for 6 weeks 
followed by a third CPET for both intervention and standard care control groups with only the 
intervention group returning to baseline levels 17. Anticipating this decline with NACRT,one of 
the leading groups in Canada performed a single group study that recruited 18 patients to 
undergo prehabilitation during NACRT 21.  
 
With a programme of supervised aerobic exercise programme (three sessions per weeks during 
NACRT) followed by an unsupervised programme (target of 150 minutes plus per week for 6-8 
weeks after NACRT), this group reported recruitment rates of 56% with no serious adverse 
events and concluded that a feasibility study was the next step.  
 
 
This study aimed to assess the feasibility of performing a physical activity intervention prior to, 
during and after NACRT in patients with rectal cancer. The primary aim was to assess feasibility 
of delivering such an intervention with indicative outcomes also recorded to inform design of a 
definitive randomised controlled trial (RCT).  
 
 
Methods 
 
From August 2014 to March 2016 (20 months), any adult over 18 years with a new diagnosis of 
rectal cancer in one NHS trust (Greater Glasgow and Clyde, GGC) was considered for inclusion in 
The REx Trial. Patients were suitable for inclusion if: pathology had confirmed an 
adenocarcinoma; pre-operative MRI staging determined the tumour was margin-threatening 
and/ or anatomically low in the pelvis; CT of chest, abdomen and pelvis showed no evidence of 
metastatic disease and their local Colorectal Cancer Multi-Disciplinary Team (MDT) had decided 
on the treatment plan of long-course neo-adjuvant chemo-radiotherapy (NACRT) followed by 
potentially curative surgery. Patients were excluded if: metastatic disease was present; their 
mobility prevented them from performing a walking intervention; they were already achieving 
their recommended government guidelines for physical activity per week (using The Scottish 
Physical Activity Screening Questionnaire)22 or had any physical, mental or psychological 
impairment that prevented signed informed consent.  
 
The trial was approved by the West of Scotland Research Ethics Service (14/WS/0079) and 
registered with ISRCTN (www.isrctn.com; 62859294; 17th March 2014). The trial was reported 
using the CONSORT 2010 Guidelines 23. This study was funded by the Chief Scientist Office 
(CZH/4/986). www.cso.scot.nhs.uk 
 
Trial Design. This was a two-arm randomised controlled feasibility study (RCT). Potentially 
eligible patients were screened by the trial team and then approached by the patient’s colorectal 
cancer nurse specialist at the time of one of their surgical or oncological consultations. The study 
co-ordinator then followed up interested participants by telephone and scheduled for consent 
and baseline testing. The colorectal surgeons in the trial team performed all written consents 
according to the standards of Good Clinical Practice. 
 
Primary Outcomes. The primary outcomes were feasibility and acceptability of the research 
procedures, as assessed by: eligibility and recruitment rates (including reasons for non-
participation); participant acceptability of randomisation, data collection and physical 
intervention; rates of retention and adherence to the physical activity intervention. Acceptability 
of randomisation was estimated from the percentage of participants attending baseline 
measurements who gave informed consent to take part in the feasibility trial. The number of 
telephone calls planned and subsequently received by each participant in the intervention group 
during the physical activity intervention measured adherence to the intervention. Trial 
satisfaction was assessed by asking each participant how much they were in agreement with the 
following 4 questions using a Likert scale from 1 (not at all in agreement) to 5 (very much in 
agreement): how satisfied were you with the REx Trial; how convenient did you find coming up 
to the hospital for trial appointments; how easy did you find the pedometer to use (intervention 
group only) and how likely would you be to recommend the REx trial to other people with rectal 
cancer? 
 
At each weekly telephone call to each participant in the intervention group, the research 
assistant was asked to grade the fidelity of the intervention using a Likert score (1- poor to 5 – 
high). Any protocol deviations were recorded. 
 
Secondary Outcomes. The primary efficacy outcome was median step count per day. Other 
secondary outcomes included physical, psychological and peri-operative variables. All outcomes 
were assessed at baseline testing pre-intervention (Baseline Test 1 prior to undergoing NACRT) 
and repeated post-intervention (1-2 weeks pre-surgery, Test 2) with peri-operative variables 
collected within the first few weeks after surgery [Figure 1].   
 
 
In addition to demographic and clinico-pathological characteristics the following physical 
measurements were taken: weight; height; hip and waist circumference; sit-to-stand test and 6 
minute walking test (6MWT). Waist circumference was measured with a measuring tape, with 
participants in the standing position and the tape positioned midway between the lateral lower 
rib margin and the iliac crest 24. If these landmarks could not be identified, the measurement was 
taken at the level of the umbilicus. Hip measurement was taken around the widest portion of 
the buttocks. Both measurements were taken twice. Weight and height allowed calculation of 
Body Mass Index (BMI): weight (kg)/[height (m)2]. Sit-to-stand test was administered over 30 
seconds, during which each participant crossed their arms and moved from sitting to full 
standing position (body straight). This was repeated as many times as possible during the 
timeframe to allow assessment of functional lower extremity strength that has been validated 
in many groups, especially older adults 25. The 6MWT is an objective measurement of functional 
exercise capacity that in addition to being safe in a variety of populations, has shown good 
correlation with 12 minute walk test and cycle ergometer and treadmill exercise tests 26,27. A flat, 
indoor surface was selected with markers placed 12.5m apart. Participants were then requested 
to walk as far as they could in the 6 minutes with the final distance being recorded (m).  
 
At the end of the baseline testing each participant was instructed on how to use the 
accelerometer that recorded data for 3-5 days. The activPAL (activPAL3, PAL Technologies, 
Glasgow, UK) is a small (53 x 35 x 7mm) lightweight (15g) triaxial accelerometer that was gently 
placed over their anterior thigh with an adhesive dressing, allowing anonymous data collection. 
Data were uploaded using the activPAL software allowing sedentary time, active time and 
average steps walked per day to be calculated from each participant. Mean daily step counts 
were categorised as follows: sedentary <5000steps/day; mildly active 5000-6999; moderately 
active 7000- 10999 and very active ≥11000 steps/ day 28. Each participant repeated this after Test 
2.  
 
Questionnaires. Each participant completed the following at pre-NACRT and post-NACRT 
testing: Becks Depression Inventory (BDI-II), FACT-C, PANAS, EORTC-QLQ CR29 and C30.  The 
existence and severity of symptoms of depression was measured using BDI-II 29. A total of 21 
items are summed to give a single point score: 0-13 normal or minimal depression; 14-19 mild; 20-
28 moderate and 29-63 severe. Colorectal cancer specific quality of life was measured using the 
Functional Assessment of Cancer Therapy – Colorectal (FACT-C). This includes 27 items from the 
FACT-General (FACT-G) and adds in 11 items specific to colorectal cancer, with a higher score 
indicating a better quality of life and a change of at least 2 being stated as clinically relevant 30. 
The Positive and Negative Affect Schedule (PANAS) is a 20-item self-reported measure of two 
scales, one to measure positive affect (where higher scores represent higher levels of positive 
affect) and the other, negative affect (where lower levels represent lower levels of negative 
affect) 32. EORTC QLQ-C30 is the widely used and validated quality of life questionnaire for all 
cancer patients by the European Organisation for Research and Treatment of Cancer. It 
comprises nine multi-item scales and six single item scales. EORTC QLQ-C29 specifically assesses 
quality of life in colorectal cancer patients and was administered alongside the C-30 32. 
 
Randomisation. Participants were randomised 1:1 to either the physical intervention or control 
group (standard care) using block size 4 and no stratification. Randomisation was performed 
using an interactive voice response (IVR) telephone system provided by the Robertson Centre 
for Biostatistics. After each participant had completed pre-NACRT testing, the research assistant 
received the group allocation via the IVR system and provided it to the participant.  The testers 
were blinded to the group allocation throughout as were their surgeons, nurse specialists and 
hospital staff involved in their care. 
 
 
Physical Activity Intervention. Participants randomized to the intervention group had an initial 
face-to-face consultation with the study co-ordinator who had been trained in the application of 
two behavioural theoretical frameworks:  self-regulatory theory (providing techniques to 
improve impulse control allowing walking targets to be reached) and the health action process 
approach (replacing behaviours that compromise health with those that enhance health) 33,34. 
 
The walking programme started prior to NACRT and was of minimum 13 weeks duration: 5 weeks 
of NACRT followed by minimal time interval of 8 weeks prior to surgery determined by individual 
surgeon’s usual practice. The programme was based on targeted stepping counts: the first 8 
weeks consisted of graduated goals calculated from the baseline stepping count (identified from 
the pre-NACRT accelerometer result) with that behaviour then maintained or increased over the 
remaining weeks up to surgery. Each participant was given a weekly walking diary (targets and 
motivational material included) and the use of the pedometer explained. Participants then 
received follow-up telephone calls (weeks 1,3,5,7,9,12,16) where new stepping targets were set, 
motivational techniques applied and any issues discussed. All participants were asked to engage 
a support person (e.g. spouse) to assist in their adherence with the programme.  
 
The target was for the participants to increase their average daily step count by 3000 
accumulated above their baseline value which is a protocol that has been used successfully by 
this research team before and other researchers 28,35,36,37,38. This is based on the assumption that 
an adult walking at a moderate pace produces 100 steps/ minute. Therefore an increase of 3000 
steps in one day is equal to 30 minutes extra activity that if performed on five days of the week 
would correspond to approximately 150 minutes of moderate physical activity over the course 
of the week which is the recommended physical activity level for adults in Scotland 22.  
 
 
Below is an example: 
Weeks 1-2: extra 1500 steps on at least 3 days a week. 
Weeks 3-4: extra 1500 steps on at least 5 days a week.  
Weeks 5-6: extra 3000 steps on at least 3 days a week.  
Weeks 7-8: extra 3000 steps on at least 5 days a week.  
Weeks 9-17: maintenance of weeks 7-8 or individually increased. 
 
Control Group. The control group received standard care with no contact from the trial team 
except at the two test sessions. When informed of their allocation to the control group, they 
were told to maintain their normal level of physical activity. They were offered a voluntary 
exercise counselling session and information pack from the trial team after their surgery and on 
completion of the trial. 
 
Neo-Adjuvant Chemoradiotherapy (NACRT). Radiotherapy dose was standardised at 4500 cGY 
in 25 fractions on weekdays only accompanied by oral Capecitabine 900mg/ m2 bd on the same 
days or 5FU 350 mg/m2 iv on weeks 1 and 5. 
 
Peri-operative Outcome Variables. For each participant that underwent surgery the following 
were recorded: length of hospital stay; surgery type; number of post-operative complications 39. 
In addition, pathology of the resected specimen was recorded.  
 
Sample Size. This was a phase 1 feasibility study to test practical aspects of the study design and 
to help inform the calculation of effect sizes for a subsequent definitive fully powered RCT. From 
The West of Scotland Colorectal Cancer Managed Clinical Network 2013 - 2014 data, 
approximately one hundred patients per year were deemed eligible for inclusion in this study.  
We estimated that we could recruit 80 patients during the planned 18-month trial recruitment 
period (40 intervention and 40 control), which would provide sufficient data to determine 
feasibility.  
 
Statistical Analysis. The main aim was to assess feasibility of intervention delivery to inform 
design of a main trial, thus the indicative outcomes are underpowered for statistical 
interpretation. Descriptive tables to summarise the feasibility measures by each group were 
performed, with means and standard deviations or medians and interquartile ranges (IQR) 
calculated for continuous variables, depending on whether or not they were normally 
distributed; and counts and percentages for categorical variables.  Wilcoxon tests were used to 
compare satisfaction scores between study groups.   
 
The most relevant physical outcome (measured average daily step count) was compared 
between groups using a linear regression model fitted to change from baseline, adjusting for the 
number of steps per day at baseline, age and gender, and presented as a mean estimate of the 
group difference with a corresponding 95% confidence interval. Study group comparisons of 
change from baseline in other physical and psychological outcome measures were carried out 
using two-sample t-tests and within-group comparisons for all measures of within-patient 
change from baseline to follow-up using paired t-tests, and both were presented as mean 
estimates and corresponding 95% confidence intervals. The EORTC-C29 embarrassment measure 
was compared from baseline to follow-up within groups using multinomial tests, and change 
from baseline between groups was assessed using a Fisher’s exact test.  
 
All statistical analysis was undertaken using R for Windows version 3.4.1 or the SAS application 
software (version 9.3, SAS Institute Inc., Cary, NC, USA). 
Results 
Feasibility. 
During the trial’s timeframe a total of 296 patients were diagnosed with rectal cancer, with 78 
put forward by their MDT for NACRT (26%) [Figure 1, Consort Diagram]. Screening showed that 
all 78 patients were eligible for the trial and were approached, with 48 patients attending for 
baseline testing and consent (recruitment rate 62%). The main reasons given for not participating 
were: ‘too much going-on’ and ‘overwhelmed by diagnosis’. No patients were excluded for 
achieving the recommended government guidelines for physical activity per week. 
 
All participants completed baseline testing and randomisation with 24 participants randomised 
to the intervention group [Table 1]. Median walking intervention duration of 14 weeks (IQR 13-
17) was completed with 80% of planned telephone calls to the intervention group being achieved 
and 75% completing the intervention [Table 1].   
 
Overall, a total of 8 participants did not complete the study: 6 from the intervention group and 
2 controls (retention rate 83%). Two of the intervention group withdrew prior to starting the 
intervention and of the remaining 6 drop-outs, 4 were for medical reasons {Figure 1]. There were 
no serious adverse events reported and no treatment pathways were modified as a consequence 
of trial participation. 
 
At the end of the trial, participants from both groups reported high levels of satisfaction with 
the trial and would recommend to other patients [Table 1]. Intervention fidelity assessments 
found an overall mean score of 4.0 (range 1-5) for the telephone-guided intervention. Deviations 
from the protocol included several attempts by the research assistant to contact participants on 
their telephone and modifying the weekly target step count depending on the participant’s 
weekly clinical status. 
 
Baseline Participant Characteristics. 
Participants had a mean age of 65.9 years (range 33.7-82.6) and were: predominately male (65%) 
and of white ethnicity (96%) and all were educated to at least completion of secondary education. 
38% of participants were from the two most deprived socioeconomic groups. Co-morbidities 
were present in 57%, with hypertension (present in 59% of those with co-morbidities) and arthritis 
(30%) most commonly recorded [Table 2].  
 
Most (60%) participants currently or had previously smoked, 88% reported current alcohol 
consumption, 71% were overweight (BMI≥25) with 19% obese (≥30). The majority of participants 
(90%) stated they could complete a flight of stairs without stopping; however, on average were 
only active for 1.6 hours a day (6.6% of their week).  The mean number of steps per day of all 
participants was 7392 (range 1151 to 17422) with 54% classified as sedentary or only slightly active 
[Table 3]. In relation to psychological testing, participants did not report being depressed [BDI 
mean score 7.2 (6.6)] and had a reasonable quality of life although fatigue and embarrassment 
were commonly reported [Table 3].  
  
Follow-up Testing. 
Results from follow-up testing are displayed in Table 4. For the primary efficacy outcome (mean 
of the median daily step count), both groups recorded a reduction in step count: the intervention 
group dropped by a mean of 1105 steps (15% reduction from baseline), whilst the control group 
reported a greater drop of 1853 steps (24% reduction from baseline) [Figure 2]. This difference 
between groups in change from baseline of 785 [95% CI -1194,2765] was not significant (adjusted 
for baseline median daily step count, age and gender).  
 
A higher percentage of the intervention group achieved step count improvements at 12 weeks 
(23.5 versus 15.8%). The intervention group also documented a non-significant mean increase of 
13.7m in their 6MWT scores, while the control group showed a mean 54.8m reduction, which 
resulted in a non-significant between-group difference of 68.5m (95% CI [-27.2,164.2]).  
There were no statistically significant changes within and between groups in relation to any of 
the psychological questionnaires. 
  
 Peri-operative Outcome Variables. 
Table 5 describes the clinico-pathological factors in all participants finding the majority 
successfully completed NACRT (98%). Most participants (36 out of 40) underwent surgery with 
33 being of curative intent, 2 local excision due to poor fitness and 1 had a defunctioning stoma 
performed. Of the 4 patients that did not undergo surgery, 3 had progressive disease on their 
post-NACRT imaging with the other participant having a complete response to NACRT on follow-
up imaging.  
 
The majority of surgery was performed electively (97%), by an open approach (72%) with a 
permanent end-colostomy formed in 61%. All grades of post-operative complications were 
recorded in 67% of cases with T3 N0 being the most commonly recorded pathological TNM 
staging.  The tumour was completely resected (R0) in 86% of surgical procedures. 
 
Discussion 
This is the first RCT to assess the feasibility of performing a walking intervention (prehabilitation) 
in patients with rectal cancer undergoing NACRT and with good recruitment, good retention and 
high participant satisfaction with trial procedures, all without compromise to the planned 
treatment pathway, these results support proceeding to a future definitive multi-centred RCT.  
 
The demographics of the participants shows that performing a walking intervention is feasible 
in groups that can be considered challenging in both recruitment and adherence; older adults 
(40% were over 70), those with high levels of socioeconomic deprivation (38%) and in patients 
with co-morbidities, including potentially activity limiting conditions, such as arthritis. 
Furthermore many participants reported smoking, alcohol consumption and being overweight, 
in addition to high levels of sedentary behaviour. Many of these factors either by themselves or 
in combination are traditionally associated with a patient potentially being labeled as ‘high risk’ 
for treatment morbidity and mortality, a statement that is supported by the reported 
complication rate of 67% in this study. Indeed, previous work has found that such patients 
account for 85% of peri-operative complications making them a key area to target, yet despite 
this, many prehabilitation protocols have excluded such patients 40. One recently published RCT 
supports our findings by recruiting only high-risk patients going straight to major abdominal 
surgery, defining high-risk as age greater than 70 years and/ or American Society of 
Anaesthesiologists score III/ IV 41. With a mean intervention time of 6 weeks to perform a 
multimodal prehabilitation programme (lifestyle counseling, nutrition assessment, iron therapy 
as appropriate accompanied by a physical activity programme) the authors reported 54 out of 
73 completed the intervention (73%) with no serious adverse events. In addition, these authors 
found a significant reduction in post-operative complications in the prehabilitation group 
compared to the usual care controls (31% versus 62%; p=0.001).  
 
These results suggest that not only is prehabilitation feasible in high-risk patients, but that their 
risk of complications can be modified.  
 
The reduction in daily step counts of the participants confirms the previously reported negative 
effect that NACRT has on physical function in patients with rectal cancer 17. Anticipating this with 
a walking intervention is a proactive approach that may offset this decline and indeed, the 
intervention group step count results show early promise from this study. However, a definitive 
trial needs be powered for daily step count as its primary aim and as such, consideration must 
be given to delivering an optimal intervention that leads to the majority of participants in the 
intervention group achieving improved step counts. Previous success with this individualized 
walking programme has been achieved in older adults, and over shorter time frames than in this 
study highlighting that there is no obvious reason why this patient population cannot achieve 
similar targets 35,36,37,42. Previous focus group work has mentioned the role that the exercise 
counselor has and increased contact time via weekly phone calls, telephone line to call in with 
questions and/ or face-to-face meetings could potentially increase motivation and adherence to 
step targets. There is also potential for repeating tests (including 6MWT and accelerometer) at 
an earlier stage, including immediately upon completion of NACRT. In addition to directly 
assessing the direct influence of the walking programme on the expected physical deterioration 
with NACRT, regular feedback may be a powerful motivational tool. 
 
 In addition, specific strategies for dealing with patient reported fatigue may optimize the 
intervention as, anecdotally, fatigue was a commonly reported reason for the participant 
reporting difficulty performing their prehabilitation. Consideration must also be given to 
educating all the health professionals that are involved in each patient’s care to ensure that each 
participant is encouraged through their prehabilitation as they would be in all aspects of their 
treatment. This need for education is reflected in the two main refusal reasons for participation: 
‘too much going-on’ and ‘overwhelmed by diagnosis’.  
 The colorectal nurse specialists performed the initial approach and, at the outset, many were 
unaware or uncertain about the definition of prehabilitation and its potential role whilst 
undergoing treatment and its influence on long-term cancer related outcomes 43,44,45. With 
education through face-to-face meetings and invited presentations at colorectal nurse meetings, 
in addition to their own patients’ feedback, a culture change occurred. With nurse specialists 
documented as a preferred source of information for cancer patients, consideration to 
education for these specialists should be integrated in the future trial protocol 46.  
 
Limitations. 
The authors acknowledge limitations of this predominately single-centred feasibility study. 
Selection bias cannot be excluded with motivated patients potentially more likely to participate. 
Furthermore, adherence to the walking intervention was self-reported and future work could 
consider including objective measures to monitor. In addition, the target of 80 patients was not 
achieved in this feasibility trial, primarily because the total number of rectal cancer patients being 
diagnosed and planned to undergo NACRT had declined slightly from the previous year reflecting 
the natural diagnostic variation that could potentially be overcome with a large multi-centred 
trial. In addition, with the interest in defining ‘complete responders’ to NACRT (no residual 
disease on post-NACRT imaging), it is entirely possible that in the coming years, the number of 
patients being referred for NACRT will increase due to early rectal cancers (stages I or II) also 
being considered for NACRT. 
 
 
 
 
Conclusion. 
This is the first RCT to assess the feasibility of performing a walking intervention (prehabilitation) 
in rectal cancer patients undergoing NACRT followed by potentially curative surgery. In addition 
to integrating around the multi-modal and sometimes rapidly changing treatment pathway, 
prehabilitation was found to be feasible in a predominately inactive, co-morbid, older adult 
population. With good recruitment, adherence and retention rates and the possibility of 
reducing the physical deterioration of NACRT, these results support the development of a fully 
powered trial to investigate the influence of prehabilitation on optimising physical function and 
patient related outcomes. 
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Table 1: Feasibility outcomes in the REx Trial: Subject Participation and satisfaction scores. 
 
Participation 
 
    
All Participants 
 
    
 
Recruited 
   
48 
 
Screening visit and Test 1 completed   48 (100%)  
Randomisation visit completed   48 (100%)  
Test 2 completed   40 (83%)  
     
Intervention group (n=24) 
 
    
 
Diary and walking intervention 
completed  
   
 
18 (75%) 
 
 
Number of completed intervention weeks 
  
Median (IQR) 
 
14 (13-17) 
 
  Range 0-17  
     
Total number of Telephone calls  Planned 116  
  Performed 93 (80%)  
     
No of telephone calls per participant  Median (IWR) 5(4-6)  
  Range 1-6  
 
 
    
Satisfaction Scores 
 
ALL Intervention 
 
Control  
 Median (IQR) 
 
Median (IQR) 
 
Median (IQR) 
 
P value 
How satisfied were you with The REx Trial 
 
5.0 
(4.0-5.0) 
5.0 
(5.0-5.0) 
4.5 
(4.0-5.0) 
0.019 
How convenient did you find coming up to 
the hospital for trial appointments? 
 
4.0 
(4.0–5.0) 
4.0 
(4.0-5.0) 
4.0 
(3.0-5.0) 
0.120 
For the intervention group: How easy did 
you find the pedometer to use? 
 
5.0 
(5.0-5.0) 
5.0 
(5.0-5.0) 
  
How likely would you be to recommend 
The REx Trial to other people with a 
diagnosis of rectal cancer 
5.0 
(4.0–5.0) 
5.0 
(4.0–5.0) 
5 
(4.0.5.0) 
0.230 
*Scored using Likert scale from 1 (not at all in agreement) to 5 (very much in agreement). 
Table 2: Comparison of Demographics, Co-morbidities and Lifestyle Factors of Participants with 
Rectal Cancer recruited to the REx Trial: Intervention group versus Control group. 
 
 
 
Statistic 
All 
(N = 48) 
Intervention 
(N = 24) 
Control 
(N = 24) 
Age (years) Nobs (Nmiss) 46 (2) 24 (0) 22 (2) 
 Mean (SD) 65.9 (10.5) 65.2 (11.4) 66.5 (9.6) 
Sex Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   Male N (%) 31 (65%) 18 (75%) 13 (54%) 
   Female N (%) 17 (35%) 6 (25%) 11 (46%) 
Ethnicity Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   White N (%) 46 (96%) 22 (92%) 24 (100%) 
   Asian, Asian Scottish or Asian British N (%) 1 (2%) 1 (4%) 0 (0%) 
   African N (%) 1 (2%) 1 (4%) 0 (0%) 
Education level Nobs (Nmiss) 44 (4) 20 (4) 24 (0) 
   Secondary Education N (%) 21 (48%) 11 (55%) 10 (42%) 
   Higher/Further Education N (%) 19 (43%) 8 (40%) 11 (46%) 
   Other N (%) 4 (9%) 1 (5%) 3 (12%) 
SIMD Nobs (Nmiss) 47 (1) 23 (1) 24 (0) 
   1 (most deprived) N (%) 9 (19%) 4 (17%) 5 (21%) 
   2 N (%) 9 (19%) 6 (26%) 3 (12%) 
   3 N (%) 13 (28%) 7 (30%) 6 (25%) 
   4 N (%) 10 (21%) 4 (17%) 6 (25%) 
   5 (least deprived) N (%) 6 (13%) 2 (9%) 4 (17%) 
ASA Nobs (Nmiss) 47 (1) 23 (1) 24 (0) 
   1 N (%) 0 (0%) 0 (0%) 0 (0%) 
   2 N (%) 32 (68%) 18 (78%) 14 (58%) 
   3 N (%) 15 (32%) 5 (22%) 10 (42%) 
   4 N (%) 0 (0%) 0 (0%) 0 (0%) 
   5 N (%) 0 (0%) 0 (0%) 0 (0%) 
Co-morbidities Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
   No N (%) 20 (43%) 12 (50%) 8 (35%) 
   Yes N (%) 27 (57%) 12 (50%) 15 (65%) 
Diabetes Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 25 (93%) 10 (83%) 15 (100%) 
   Yes N (%) 2 (7%) 2 (17%) 0 (0%) 
BMI Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   <20 N (%) 2 (4%) 2 (8%) 0 (0%) 
   20-24.9 N (%) 12 (25%) 8 (33%) 4 (17%) 
   25-29.9 N (%) 25 (52%) 12 (50%) 13 (54%) 
   30-34.9 N (%) 8 (17%) 2 (8%) 6 (25%) 
   35+ N (%) 1 (2%) 0 (0%) 1 (4%) 
Hypertension Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 11 (41%) 5 (42%) 6 (40%) 
   Yes N (%) 16 (59%) 7 (58%) 9 (60%) 
COPD Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 25 (93%) 11 (92%) 14 (93%) 
   Yes N (%) 2 (7%) 1 (8%) 1 (7%) 
MI Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 24 (89%) 10 (83%) 14 (93%) 
   Yes N (%) 3 (11%) 2 (17%) 1 (7%) 
CVA Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 26 (96%) 11 (92%) 15 (100%) 
   Yes N (%) 1 (4%) 1 (8%) 0 (0%) 
Arthritis Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 19 (70%) 9 (75%) 10 (67%) 
   Yes N (%) 8 (30%) 3 (25%) 5 (33%) 
Other co-morbidities Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 22 (81%) 10 (83%) 12 (80%) 
   Yes N (%) 5 (19%) 2 (17%) 3 (20%) 
Weight (kg) Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
 Mean (SD) 76.2 (11.4) 75.4 (13.4) 77.0 (9.1) 
Smoking Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   Current N (%) 7 (15%) 4 (17%) 3 (12%) 
   Ex (<12 months) N (%) 10 (21%) 7 (29%) 3 (12%) 
   Ex (>=12 months) N (%) 12 (25%) 4 (17%) 8 (33%) 
   Never smoked N (%) 19 (40%) 9 (38%) 10 (42%) 
Alcohol consumption Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   Excess N (%) 4 (8%) 1 (4%) 3 (12%) 
   Previous excess N (%) 4 (8%) 2 (8%) 2 (8%) 
   Within limits N (%) 34 (71%) 18 (75%) 16 (67%) 
   None N (%) 6 (12%) 3 (12%) 3 (12%) 
Physical activity: Climb flight of stairs:- Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   Unable N (%) 2 (4%) 0 (0%) 2 (8%) 
   With stopping N (%) 3 (6%) 2 (8%) 1 (4%) 
   Without stopping N (%) 43 (90%) 22 (92%) 21 (88%) 
 
 
 
Table 3: Comparison of Baseline Physical and Psychological Measurements of REx Trial 
Participants: Intervention group versus Control group. 
  
All 
(N = 48) 
Intervention 
(N = 24) 
Control 
(N = 24) 
Median steps per day Nobs (Nmiss) 46 (2) 23 (1) 23 (1) 
 Mean (SD) 7392 (3765) 7162 (3193) 7623 (3684) 
 Range 1152, 17422 1526, 17422 1152, 16472 
Sedentary N (%) 12 (26.1%) 8 (34.8%) 4 (17.4%) 
Slightly active N (%) 13 (28.3%) 5 (21.7%) 8 (34.8%) 
Moderately active N (%) 17 (37.0%) 8 (34.8%) 9 (39.1%) 
Very active N (%) 4 (8.7%) 2 (8.7%) 2 (8.7%) 
Waist circumference (cm) Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
 Mean (SD) 96.1 (9.4) 95.3 (11.1) 96.9 (7.6) 
Sit-to-stand test   (no. in 30 secs) Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
 Mean (SD) 11.3 (3.0) 11.3 (3.1) 11.4 (3.0) 
6 minute walking tests (m) Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
 Mean (SD) 436.2 (79.2) 435.7 (91.7) 436.7 (66.4) 
% of week spent active Nobs (Nmiss) 46 (2) 23 (1) 23 (1) 
 Mean (SD) 6.6 (2.8) 6.5 (2.8) 6.7 (2.9) 
% of week spent sedentary Nobs (Nmiss) 46 (2) 23 (1) 23 (1) 
 Mean (SD) 76.4 (12.1) 77.9 (7.3) 74.9 (15.6) 
EORTC-C30 Fatigue* Nobs (Nmiss) 46 (2) 23 (1) 23 (1) 
 Mean (SD) 23.9 (22.3) 27.5 (23.4) 20.3 (21.1) 
EORTC-C29 Embarrassment* Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
   Not at all N (%) 27 (57.4%) 14 (58.3%) 13 (56.5%) 
   A little N (%) 11 (23.4%) 4 (16.7%) 7 (30.4%) 
   Quite a bit N (%) 1 (2.1%) 1 (4.2%) 0 (0.0%) 
   Very much N (%) 8 (17.0%) 5 (20.8%) 3 (13.0%) 
PANAS     
Positive affect score Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
 Mean (SD) 33.6 (9.9) 35.0 (11.5) 32.1 (7.9) 
Negative affect score Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
 Mean (SD) 17.6 (7.0) 18.5 (7.4) 16.6 (6.5) 
BDI-II Nobs (Nmiss) 47 (1) 23 (1) 24 (0) 
 Mean (SD) 7.2 (6.6) 7.9 (7.3) 6.5 (6.1) 
Fact-C total score Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
 Mean (SD) 63.9 (10.9) 66.0 (8.6) 61.7 (12.8) 
* Selected results shown 
 
 
Table 4: Comparison of Changes in Physical and Psychological Measurements between Intervention and Control groups (Test 2 versus baseline Test 1). * Primary efficacy 
outcome   
** Adjusted for number of steps at baseline, age and gender. 
 
Intervention Control 
Group difference  
(Intervention – Control)  
N Mean (SD) Change from baseline (95% CI) N Mean (SD) Change from baseline (95% CI) Mean (95% CI) 
Median steps per day* 
Baseline 
17 
7779 (4045) 
-1105 (-2802, 593) 19 
7773 (3975)  
785 (-1195, 2765)** 
12 week 6675 (3100) 5920 (3152) -1853 (-3871, 164) 
Weight (kg) 
Baseline 
18 
76.7 (10.1) 
1.3 (-0.4, 3.0) 20 
77.3 (7.8)  
0.5 (-2.1, 3.1) 
12 week 78.0 (11.6) 78.2 (8.9) 0.8 (-1.2, 2.9) 
BMI 
Baseline 
18 
26.5 (3.0) 
0.3 (-0.2, 0.8) 20 
28.0 (3.4)  
0.2 (-0.6, 1.1) 
12 week 26.8 (3.4) 28.1 (3.3) 0.1 (-0.6, 0.8) 
Waist circumference (cm) 
Baseline 
18 
96.0 (9.7) 
-2.2 (-8.8, 4.4) 21 
97.7 (7.4)  
-4.4 (-11.3, 2.5) 
12 week 93.8 (17.9) 99.9 (7.7) 2.2 (-0.1, 4.5) 
Sit-to-stand test 
(no.completed in 30 secs) 
Baseline 
18 
11.5 (2.5) 
-0.4 (-2.2, 1.4) 22 
11.5 (3.0)  
-0.6 (-3.3, 2.2) 
12 week 11.1 (4.2) 11.7 (6.1) 0.1 (-2.1, 2.4) 
6 minute walking tests 
(m) 
Baseline 
18 
448.8 (64.9) 
13.7 (-50.1, 77.5) 22 
444.9 (59.2)  
68.5 (-27.2,164.2) 
12 week 462.5 (144.3) 390.1 (159.4) -54.8 (-130.4, 20.7) 
% of week spent active 
Baseline 
17 
6.6 (2.9) 
-0.8 (-2.1, 0.4) 19 
6.9 (3.1)  
0.3 (-1.7, 2.2) 
12 week 5.8 (2.6) 5.8 (2.3) -1.1 (-2.7, 0.5) 
% of week spent 
sedentary 
Baseline 
17 
76.0 (5.3) 
0.4 (-2.8, 3.6) 19 
74.8 (17.2)  
-2.7 (-13.2, 7.9) 
12 week 76.4 (7.6) 77.9 (7.6) 3.1 (-7.1,13.3) 
EORTC-C30 Fatigue 
Baseline 
17 
28.1 (23.6) 
0.7 (-13.7, 15.0) 20 
18.3 (19.8)  
-6.6 (-21.7, 8.5) 
12 week 28.8 (23.9) 25.6 (16.9) 7.2 ( 1.8,12.6) 
Positive affect score 
Baseline 
18 
36.2 (11.1) 
-3.7 (-10.2, 2.9) 20 
33.0 (8.0)  
-3.7 (-11.5, 4.2) 
12 week 32.5 (7.4) 33.0 (8.0) 0.0 (-4.7, 4.7) 
Negative affect score 
Baseline 
18 
18.9 (7.8) 
1.1 (-2.0, 4.2) 20 
16.1 (5.9)  
1.5 (-2.8, 5.8) 
12 week 20.0 (8.3) 15.7 (6.5) -0.4 (-3.7, 2.8) 
BDI-II 
Baseline 
15 
7.3 (5.9) 
0.7 (-1.7, 3.2) 22 
5.5 (4.4)  
-0.7 (-3.8, 2.5) 
12 week 8.1 (6.9) 7.0 (5.2) 1.4 (-0.7, 3.5) 
Fact-C total score 
Baseline 
18 
66.7 (8.9) 
-0.2 (-6.3, 6.0) 21 
60.5 (12.7)  
0.9 (-6.2, 8.0) 
12 week 66.5 (13.5) 59.4 (11.2) -1.1 (-5.1, 2.9) 
Table 5: Comparison of Clinico-Pathological Factors in Participants with Rectal Cancer recruited 
to the REx Trial: Intervention group versus Control group (patients who completed test 2 only). 
 
  All Participants 
N=40 
 
Intervention 
N=18 
Control 
N=22 
NACRT Started  N (%) 40 (100%) 18 (100%) 22 (100%) 
 Completed  Yes: No 39 (98%) 18 (100%) 21 (95%) 
Surgery Yes: No 36 (90%) 17 (94%) 19 (86%) 
 Elective * 35 (97%) 16 (94%) 19 (100%) 
 Laparoscopic/ lap assisted: 
lap-open : open 
6 (17%):  
4 (11%): 26 (72%) 
3 (18%):  
3(18%): 11 (65%) 
3 (16%):  
1 (5%): 15 (79%) 
Type of Surgery   N (%) Anterior Resection/ 
Hartmann’s procedure 
18 (50%) 10 (59%) 8 (42%) 
 APR 15 (42%) 6 (35%) 9 (47%) 
 Local Excision/ TAMIS 2 (6%) 0 2 (11%) 
 Palliative stoma formation 1 (3%) 1 (6%) 0 
Stoma formed Yes: no 33:3 17:0 16:3 
 Permanent: temporary 20: 13 8: 9 12:4 
Complications N (%) 24 (60%) 12 (67%) 12 (55%) 
Length of stay (days) Median (range) 10.5 (0.0 -38.2) 11.0 (6.0-37.0) 10 (0.0-38.2) 
TNM Staging (post-op)** T0 8 (23%) 4 (22%) 4 (18%) 
 T1 
T2 
T3 
3 (9%) 
7 (20%) 
16 (46%) 
1 (6%) 
1 (6%) 
10 (56%) 
2 (9%) 
6 (27%) 
9 (41%) 
 T4 1 (3%) 0 (0%) 1 (5%) 
 N0¶ 20 (61%) 10 (56%) 10 (45%) 
 N1 11 (33%) 5 (28%) 6 (27%) 
 N2 2 (6%%) 1 (6%) 1 (5%) 
No. of Lymph Nodes Median (range) 13.0 (0-43) 17 (4.0-43.0) 13 (0.0-27.) 
CRM clear¶ Yes: No 30: 3 15: 2 16: 1 
R0 Resection ** Yes: No 30: 5 13: 3 17: 2 
* n=1 obstruction, perforation 
** n=1 no pathology resected, defunctioning stoma only; percentage expressed out of total of 35 operations. 
¶ n=2 local excision where no nodal resection performed; percentage expressed out of a total of 33 operations.Figure 1: The REx 
Trial Consort Diagram. 
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 Figure 2: Comparison of change in daily step count after intervention between Intervention 
and Control groups. 
 
 
